These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28817386)

  • 1. CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth.
    Reeves PM; Abbaslou MA; Kools FRW; Poznansky MC
    Anticancer Drugs; 2017 Oct; 28(9):935-942. PubMed ID: 28817386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice.
    Reeves PM; Abbaslou MA; Kools FRW; Vutipongsatorn K; Tong X; Gavegnano C; Schinazi RF; Poznansky MC
    Oncotarget; 2017 Nov; 8(55):94040-94053. PubMed ID: 29212208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCL12/CXCR4 Axis-Targeted Dual-Functional Nano-Drug Delivery System Against Ovarian Cancer.
    Xue J; Li R; Gao D; Chen F; Xie H
    Int J Nanomedicine; 2020; 15():5701-5718. PubMed ID: 32848392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
    Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
    FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
    Taylor SA; Marrinan CH; Liu G; Nale L; Bishop WR; Kirschmeier P; Liu M; Long BJ
    Gynecol Oncol; 2008 Apr; 109(1):97-106. PubMed ID: 18237771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of estrogen or progesterone combined with paclitaxel on human ovarian cancer cell growth and Drosha expression].
    Yang Y; Han K; Xie Y
    Zhonghua Zhong Liu Za Zhi; 2015 Aug; 37(8):578-84. PubMed ID: 26714597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging CXCL12-CXCR4 signaling in ovarian cancer therapy.
    Salomonnson E; Stacer AC; Ehrlich A; Luker KE; Luker GD
    PLoS One; 2013; 8(1):e51500. PubMed ID: 23372646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
    Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
    Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
    Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
    Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of thymidine phosphorylase expression and enhancement of Furtulon sensitivity by Taxol in a human ovarian carcinoma cell line.
    Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
    Anticancer Res; 2003; 23(3B):2665-9. PubMed ID: 12894555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergy between Paclitaxel and Anti-Cancer Peptide PNC-27 in the Treatment of Ovarian Cancer.
    Alagkiozidis I; Gorelick C; Shah T; Chen YA; Gupta V; Stefanov D; Amarnani A; Lee YC; Abulafia O; Sarafraz-Yazdi E; Michl J
    Ann Clin Lab Sci; 2017 May; 47(3):271-281. PubMed ID: 28667027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas.
    Redjal N; Chan JA; Segal RA; Kung AL
    Clin Cancer Res; 2006 Nov; 12(22):6765-71. PubMed ID: 17121897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
    Mayr C; Neureiter D; Pichler M; Berr F; Wagner A; Kiesslich T; Namberger K
    Mol Med Rep; 2015 Aug; 12(2):2247-52. PubMed ID: 25846744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor effect of CXCR4 antagonist AMD3100 on the tumorigenic cell line of BHP10-3 papillary thyroid cancer cells.
    Jung YH; Lee DY; Cha W; Kim BH; Sung MW; Kim KH; Ahn SH
    Head Neck; 2016 Oct; 38(10):1479-86. PubMed ID: 27061747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential combination of flavopiridol with Taxol synergistically suppresses human ovarian carcinoma growth.
    Song Y; Xin X; Zhai X; Xia Z; Shen K
    Arch Gynecol Obstet; 2015 Jan; 291(1):143-50. PubMed ID: 25118834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation Fucoidan Extracts From Undaria pinnatifida and Fucus vesiculosus in Combination With Anticancer Drugs in Human Cancer Orthotopic Mouse Models.
    Burney M; Mathew L; Gaikwad A; Nugent EK; Gonzalez AO; Smith JA
    Integr Cancer Ther; 2018 Sep; 17(3):755-761. PubMed ID: 29156992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
    Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
    Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.
    Broxmeyer HE; Orschell CM; Clapp DW; Hangoc G; Cooper S; Plett PA; Liles WC; Li X; Graham-Evans B; Campbell TB; Calandra G; Bridger G; Dale DC; Srour EF
    J Exp Med; 2005 Apr; 201(8):1307-18. PubMed ID: 15837815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.